Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07768358
PHASE4

Tucatinib Continuation Study

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.

Official title: TUCATINIB CONTINUATION PROTOCOL: AN OPEN-LABEL STUDY FOR PARTICIPANTS FROM TUCATINIB CLINICAL STUDIES

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

175

Start Date

2026-11-06

Completion Date

2032-03-13

Last Updated

2026-08-28

Healthy Volunteers

No

Interventions

DRUG

tucatinib

150 - 300 mg, by mouth, twice a day